F046 Think Like an Expert about Ichthyosis
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will be a lively, highly interactive discussion of challenging ichthyosis patient cases and updates and controversies in the field. Audience members will have a unique opportunity to observe how complex cases are approached by experts in their daily practice, as well as interact with and ask questions of these experts. A patient advocate will be present to provide the patient perspective.
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 Continuing Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Develop an approach to managing patients with unfamiliar, uncommon, and complex skin disease.
Order appropriate genetic testing for patients with ichthyosis and other inherited skin conditions.
Locate educational and support resources for patients affected by ichthyosis and their families
SCHEDULE
8:30 PM
Introductions and Agenda
Cheryl Marie Bayart, MD, FAAD
8:35 PM
Highlights of new classification guidelines
Antoni Gostynski, MD, PhD, MSc, IFAAD, Amy S. Paller, MD, FAAD
8:55 PM
The Ichthyosis Registry: Enabling new research in epidermal differentiation disorders
Keith Choate, MD, PhD, FAAD
9:10 PM
Diagnosis of rare forms of ichthyosis
Maria-Angela Hernandez-Martin, MD, IFAAD
9:25 PM
Managing painful PC: daily care and Erlotinib treatment
Janice Schwartz
9:40 PM
Pathogenesis-based treatments
Joyce Teng, MD, FAAD
9:55 PM
Biologics: are they effective in EDD
Juliette Mazereeuw-Hautier
10:10 PM
Living with ichthyosis: a patient's perspective
Denise Gass
SPEAKERS
Cheryl Marie Bayart, MD, FAAD
Keith Choate, MD, PhD, FAAD
Denise Gass
Antoni Gostynski, MD, PhD, MSc, IFAAD
Maria-Angela Hernandez-Martin, MD, IFAAD
Juliette Mazereeuw-Hautier
Amy S. Paller, MD, FAAD
Janice Schwartz
Joyce Teng, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Cheryl Marie Bayart, MD, FAAD
No financial relationships exist with ineligible companies.
Keith Choate, MD, PhD, FAAD
AbbVie – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Eli Lilly – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding);
Denise Gass
No financial relationships exist with ineligible companies.
Antoni Gostynski, MD, PhD, MSc, IFAAD
AbbVie – Advisory Board(Honoraria); Almirall – Advisory Board(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); La Roche-Posay – Other(Grants/Research Funding); Leo Foundation – Other(Grants/Research Funding); Leo Pharma – Advisory Board(Honoraria); Novo Nordisk A/S – Stockholder Public Company(Stock); Pfizer – Stockholder Public Company(Stock); Pfizer Inc. – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria), Stockholder Public Company(Stock);
Maria-Angela Hernandez-Martin, MD, IFAAD
Alexion Pharmaceuticals – Speaker/Faculty Education(Fees); Almirall – Advisory Board(Fees); Beiersdorf – Speaker/Faculty Education(Fees); Celgene – Investigator(Grants/Research Funding); Galderma – Advisory Board(Fees); La Roche-Posay - L'Oreal Group – Advisory Board(Fees), Speaker/Faculty Education(Fees); Leti – Speaker/Faculty Education(Fees); Mayne Pharma Group – Investigator(Grants/Research Funding); Novartis – Speaker/Faculty Education(Fees); Sanofi Genzyme – Advisory Board(Fees), Speaker/Faculty Education(Fees); Viatris Inc. – Advisory Board(Fees), Speaker/Faculty Education(Fees);
Juliette Mazereeuw-Hautier
No financial relationships exist with ineligible companies.
Amy S. Paller, MD, FAAD
AbbVie – Data Safety Monitoring Board(Honoraria), Investigator(Grants/Research Funding); Abeona Therapeutics – Data Safety Monitoring Board(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); BioCryst Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria), Data Safety Monitoring Board(Honoraria); BioMendics, LLC – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria); Castle Creek Pharmaceuticals – Consultant (1099 relationship)(Honoraria); Chiesi Farmaceutici – Consultant (1099 relationship)(Honoraria); Daiichi Sankyo – Data Safety Monitoring Board(Honoraria); Dermavant Sciences, Inc. – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Galderma – Data Safety Monitoring Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Johnson & Johnson Innovative Medicine – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Krystal Biotech, Inc – Consultant(Honoraria); L'Oréal France – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); Pelthos Therapeutics – Consultant (1099 relationship)(Honoraria); Quoin Pharmaceuticals Ltd – Consultant (1099 relationship)(Honoraria); Regeneron – Consultant(Honoraria), Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding);
Janice Schwartz
No financial relationships exist with ineligible companies.
Joyce Teng, MD, FAAD
Abeona – Consultant(Fees); AFT Pharmaceuticals – Consultant(Fees); Amryt Pharma – Consultant(Fees); Eden Brand – Advisory Board(Fees); Novartis – Investigator(Grants/Research Funding); Palvella Therapeutics – Consultant(Fees);